Pfizer's Braftovi to command 42% share of BRAF inhibitors melanoma market by 2028

Since Roche's Zelboraf (vemurafenib)gained FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations in melanoma.